Guardant Health (NASDAQ:GH) and Aeon Global Health (OTCMKTS:AGHC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.
Valuation & Earnings
This table compares Guardant Health and Aeon Global Health’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Guardant Health||$90.64 million||92.70||-$240.11 million||($2.80)||-34.99|
|Aeon Global Health||$16.30 million||0.19||-$8.00 million||($1.15)||-0.37|
Insider and Institutional Ownership
69.5% of Guardant Health shares are owned by institutional investors. 11.5% of Aeon Global Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Guardant Health and Aeon Global Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aeon Global Health||-29.16%||-290.44%||-38.31%|
This is a breakdown of recent ratings and target prices for Guardant Health and Aeon Global Health, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aeon Global Health||0||1||0||0||2.00|
Guardant Health presently has a consensus price target of $72.50, suggesting a potential downside of 26.01%. Given Guardant Health’s stronger consensus rating and higher possible upside, equities analysts clearly believe Guardant Health is more favorable than Aeon Global Health.
Guardant Health beats Aeon Global Health on 9 of the 13 factors compared between the two stocks.
Guardant Health Company Profile
Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Aeon Global Health Company Profile
Aeon Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States. The company operates through Laboratory Testing Services and Web-Based Software segments. Its laboratory testing services include the testing of an individual's blood, urine, or saliva for the presence of drugs or chemicals, as well as the patient's DNA profile. The company primarily offers medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. It also provides Web-based services as software as a service for Web-based revenue cycle management applications; and telehealth products and services that enable healthcare organizations to coordinate care for patients, and enhance related administrative and clinical workflows, as well as compliance with regulatory requirements. In addition, AEON Global Health Corp. offers post contract customer support services. The company was formerly known as Authentidate Holding Corp. and changed its name to Aeon Global Health Corp. in January 2018. Aeon Global Health Corp. is headquartered in Gainesville, Georgia.
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.